Van Tuyl Christopher 4

What Happened Christopher Van Tuyl, Chief Legal Officer of Immunovant (IMVT), exercised 17,824 stock options on June 26, 2026 at an exercise price of $15.20 per share (cost $270,925) and sold the resulting 17,824 shares the same day in two open-market transactions for aggregate proceeds of about $682,887. The transactions show total gross proceeds from the sales of $682,887 and an exercise cost of $270,925 (approximate net before taxes/fees of $411,962).

Key Details

• Transaction date: June 26, 2026.
• Option exercise: 17,824 shares exercised at $15.20 each (total reported cost $270,925).
• Open-market sales: 14,982 shares at a weighted avg $38.19 (proceeds $572,163) and 2,842 shares at a weighted avg $38.96 (proceeds $110,724). Footnotes report sale price ranges of $37.75–$38.70 and $38.82–$39.15 for the respective groups.
• Derivative disposition line: the option/derivative was converted/terminated upon exercise (reported as disposed at $0).
• Shares owned after the transactions: not specified in the information provided.
• Filing timeliness: report period and filing date are both June 26, 2026 — no late filing indicated in the provided data.
• Relevant footnote: the options granted had an April 1, 2025 grant date and vest 25% on April 1, 2026 with the remainder vesting monthly over the following three years.

Context This was an option exercise immediately followed by sales of the exercised shares (a same-day exercise-and-sell pattern often used to cover exercise cost and tax obligations). The filing is factual and does not disclose motivation. Purchases are generally more informative about insider sentiment; this report documents a routine exercise and sale.